TruTrace Technologies Inc (CSE:TTT) (OTCMKTS: TTTSF) announced Thursday that Aphria Inc (TSE:APHA) (NYSE:APHA) has joined Phase 2 of the Shoppers Drug Mart medical cannabis verification pilot program.
TruTrace’s blockchain-secured program is specifically designed to increase transparency, interoperability and product identification within the medical cannabis industry.
The program uses the company's StrainSecure technology as a central hub for identity management, asset tracking, validation, and product authentication. StrainSecure also serves as a master registry for standardized testing, product verification, and quality assurance.
READ: TruTrace partners with Deloitte to grow its StrainSecure retail cannabis verification technology
Shoppers Drug Mart, a large Canadian retail pharmacy chain, first announced the pilot program in June at the second annual World Cannabis Congress in Saint John, New Brunswick.
The program is expected to help researchers and clinicians match therapeutic outcomes to specific genetic and chemical profiles, and provide physicians, pharmacists, and patients with greater confidence in the products they prescribe or consume.
"We are thrilled to partner with Shoppers Drug Mart and TruTrace Technologies to increase transparency within the medical cannabis industry," Aphria Chairman Irwin Simon said in a statement.
"At Aphria Inc, we take responsibility to heart and recognize the importance of standardized testing and quality assurance. This program reflects our ongoing commitment to protecting the health and safety of our patients."
Shoppers recently announced the successful completion of Phase 1 of the pilot program and the addition of Deloitte Canada LLP in a project management and advisory role to execute Phase 2. Full production and implementation is targeted for late November 2019.
"The participation of a major licensed producer like Aphria, with their expertise and dedication to medical patients, is essential to the success of the pilot program," said Robert Galarza, CEO of Vancouver-based TruTrace.
"Together we are working to develop a unified approach to medical cannabis standards that will help ensure full traceability and consistent patient outcomes."
Under the StrainSecure program, the TruTrace team collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation.
All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the program.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham